文献速递乳腺MR

乳腺MRI非肿块强化累及乳头在新辅助化疗后缓解:病理缓解与保留乳头乳房切除术的可行性

Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy.
PubMed 文献 · Radiology · 2023-02-07

该单中心回顾性研究纳入383例基线MRI显示非肿块强化(NME)且接受新辅助化疗(NAC)后行乳房切除术的女性,评估NAC后NME累及乳头缓解者行保留乳头乳房切除术(NSM)的可行性。326例行乳头-乳晕复合体切除者中,NAC后NME累及乳头缓解者病理证实乳头肿瘤侵犯率为2.6%(4/153,95%CI:0,6.5),MRI完全缓解者无一例乳头侵犯。57例NSM中,12例NAC后NME累及乳头缓解者中位随访31个月无复发。结论认为该人群NSM可行,尤其MRI完全缓解者。

要点

  • NAC后MRI显示NME累及乳头缓解者,病理证实乳头侵犯率低(2.6%),可考虑NSM。
  • MRI完全缓解者未见乳头侵犯,支持更积极选择NSM。
  • 初始MRI NME累及乳头并非NSM绝对禁忌,NAC后缓解者可重新评估。

关键影像表现/征象

  • 基线MRI示NME累及乳头者217/326(67%),NAC后缓解者153/217(70%)。
  • NAC后NME累及乳头缓解者中,病理证实乳头肿瘤侵犯4/153(2.6%;95%CI:0,6.5)。
  • MRI完全缓解的31例中,无病理证实乳头肿瘤侵犯。

诊断标准与关键数值

  • NAC后NME累及乳头缓解者乳头侵犯率2.6%(4/153;95%CI:0,6.5)。
  • MRI完全缓解者乳头侵犯率为0(0/31)。

临床应用与阅片要点

  • 对初始MRI NME累及乳头者,NAC后应复查MRI评估缓解情况,缓解者可考虑NSM。
  • MRI完全缓解者乳头侵犯风险极低,可优先考虑NSM。
  • 报告应明确NME是否累及乳头及NAC后变化。

局限性

  • 单中心回顾性研究,选择偏倚可能存在。
  • NSM样本量较小(57例),随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Nipple-sparing mastectomy (NSM) is usually contraindicated in patients with nonmass enhancement (NME) extension to the nipple at breast MRI. However, little is known about the feasibility of NSM when NME extension to the nipple resolves after neoadjuvant chemotherapy (NAC). Purpose To evaluate whether NSM is an appropriate surgical procedure for patients in whom NME extension to the nipple resolves after NAC. Materials and Methods This retrospective study included 383 women with NME at baseline MRI who underwent NAC followed by mastectomy between January 2007 and March 2022 at a single institution. NME extension to the nipple was assessed using breast MRI before NAC (hereafter, pre-NAC) and after NAC (hereafter, post-NAC). In 326 women who underwent mastectomy with removal of the nipple-areolar complex, the rate of pathologic analysis-confirmed tumor invasion of the nipple compared with NME extension to the nipple at post-NAC breast MRI was evaluated. Tumor involvement of the nipple was also assessed in those with complete pathologic response at posttreatment MRI. Furthermore, the outcomes in 57 women undergoing NSM were investigated, particularly in patients with NME extension to the nipple at initial diagnosis. Results Of the 326 women who underwent mastectomy with removal of the nipple-areolar complex (mean age, 49 years ± 9.4 [SD]), 217 patients (67%) showed NME extension to the nipple on pre-NAC MRI scans. Among the 153 women (70%) in whom the NME extension to the nipple resolved after NAC, the rate of pathologic analysis-confirmed tumor invasion of the nipple was 2.6% (four of 153 women; 95% CI: 0, 6.5). No pathologic analysis-confirmed tumor invasion of the nipple was detected in 31 women with complete response at MRI. Of the 57 women who underwent NSM, 12 (21%) with resolution of NME extension to the nipple after NAC had no relapse during the median follow-up of 31 months (range, 11-80 months). Conclusion Pathologic analysis-confirmed tumor invasion of the nipple was rare in women with resolution of nonmass enhancement extension to the nipple after neoadjuvant chemotherapy (NAC). Therefore, nipple-sparing mastectomy could be feasible in this population, especially in those with complete MRI response to NAC. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Lee in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Bae, Ahn, Park, et al. Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy. Radiology. 2023. PMID: 36749210. doi:10.1148/radiol.221777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。